While vaccines are being developed to stop the COVID-19 pandemic, there is a major effort to prevent the high mortality associated with COVID-19 hyperinflammation. Researchers from the Vall Hebron Hospital Research Institute and IMIDomics have contributed to this endeavour by identifying abatacept, a CD80/86 co-stimulation blocking agent, as a new candidate to prevent COVID-19 to reach a life-threatening stage.


IMIDomics funds a study that identifies a new drug candidate to prevent severe COVID-19

Leave a Reply

Your email address will not be published. Required fields are marked *